Use of Funds
$15M funding to launch three tests and begin to revenue
Sources
Investor Capital
$15,000,000
Total
$15,000,000
Uses
Product Development
$2,500,000
Inventory / Materials
$500,000
Sales / Marketing
$3,000,000
Operating Costs
$3,500, 000
Regulatory Costs
$3,500,000
Manufacturing / Ramp-Up
$1,200,000
Transaction Expenses / Fees
$800,000
Total
$15,000,000
To date: IP development of StromaGenesis funded using ~$10MM in Grants [NIH/DOD/State Funds]
CEO Richard Pestell, MD acquired the Algorithm [asset] from CytoDyn 6/22 [BDO Valuation $9.6MM]
CEO Richard Pestell, MD acquired additional assets on 6/22 [~$1.5MM expended]
These funds have provided verification of the algorithm and Clinical Trial materials supported by 36 publications.
100 East Lancaster Ave
Room R234
Wynnewood, Pennsylvania 19096
